Table 1 Patient characteristics at baseline
Parameter | Total (n = 98) | Fractured (n = 20) | Non-fractured (n = 78) |
|---|---|---|---|
Age (years old) | 69 (65–74) | 71 (67–75) | 69 (65–74) |
BMI (kg/m2) | 20.4 (18.7–22.9) | 20.1 (17.8–21.2) | 20.5 (19.0–23.4) |
Disease duration (months) | 80 (8–209) | 180 (56–270) | 63 (6–162) |
History of vertebral fracture, n (%) | 27 (27.6) | 14 (70.0) | 13 (16.7) |
SDAI | (3.83–12.00) | 7.24 (4.70–11.87) | 6.73 (3.72–12.00) |
HAQ-DI | 0.50 (0.13–1.13) | 1.00 (0.50–1.63) | 0.44 (0.13–1.00) |
Rheumatoid factor positive, n (%) | 72 (73.5) | 16 (80.0) | 56 (71.8) |
Rheumatoid factor (IU/mL) | 45 (14–89) | 41 (23–80) | 45 (14–89) |
ACPA positive, n (%) | 75 (76.5) | 16 (80.0) | 59 (75.6) |
ACPA (U/mL) | 25 (5–250) | 33 (8–366) | 35 (3–234) |
CRP (mg/dL) | 0.18 (0.04–0.67) | 0.09 (0.01–0.83) | 0.19 (0.05–0.58) |
Concomitant oral glucocorticoid, n (%) | 49 (50.0) | 13 (65.0) | 36 (46.1) |
Dose of oral glucocorticoid (mg/day) | 0.2 (0–3.8) | 2.5 (0–3.0) | 0 (0–5.0) |
Dose of oral glucocorticoida (mg/day) | 4.0 (2.5–5.0) | 3.0 (2.5–3.5) | 5.0 (2.5–7.5) |
Concomitant methotrexate, n (%) | 78 (79.6) | 16 (80.0) | 62 (79.5) |
Dose of methotrexate (mg/week) | 6.0 (2.0–8.0) | 4.0 (2.0–8.0) | 8.0 (4.0–8.0) |
Dose of methotrexatea (mg/week) | 8.0 (6.0–10.0) | 6.0 (4.0–8.5) | 8.0 (6.0–10.0) |
Concomitant bDMARDs, n (%) | 33 (33.7) | 9 (45.0) | 24 (30.8) |
Lumbar BMD (g/cm2) | 0.73 (0.66–0.82) | 0.73 (0.63–0.83) | 0.73 (0.66–0.81) |
Total hip BMD (g/cm2) | 0.62 (0.56–0.68) | 0.56 (0.50–0.65) | 0.62 (0.58–0.68) |
Vitamin D supplementation, n (%) | 27 (27.6) | 3 (15.0) | 24 (30.8) |
Type of oral BP, n (%) | |||
Alendronate | 14 (14.3) | 5 (25.0) | 9 (11.5) |
Risedronate | 24 (24.5) | 6 (30.0) | 18 (23.1) |
Minodronate | 60 (61.2) | 9 (45.0) | 51 (65.4) |
Length of BP treatment (months) | 28 (11–45) | 35 (16–49) | 28 (11–44) |